博雅生物(300294) - 2020年2月5日投资者关系活动记录表

Group 1: Impact of COVID-19 on Company Operations - The COVID-19 pandemic has significantly affected China's public health sector, leading to increased awareness of new pneumonia and rational drug use [2] - The company discussed its products' roles in treating severe patients, including the use of immunoglobulin and albumin for symptomatic treatment [3][4] - The pandemic is expected to enhance long-term recognition of blood products and their emergency use in clinical settings [3] Group 2: Plasma Collection and Inventory Management - The industry plasma collection volume was 9,200 tons, with recovery dependent on the lifting of gathering restrictions and the reduction of the infection coefficient to 0.4 [4] - The company has paused plasma collection to control the infection source, maintaining a two-month supply of inventory [4][5] - The company’s inventory of qualified plasma in Guangdong is approximately 800 tons, with a production timeline of about four months [7] Group 3: Demand and Usage of Immunoglobulin - The average usage of immunoglobulin in China is less than 1/10 compared to developed countries, indicating a lack of awareness [5] - In January 2020, the national usage of immunoglobulin was around 2 million doses, with a total demand in 2019 of approximately 13 million doses [5][6] - The treatment guidelines suggest a dosage of 0.25 grams of immunoglobulin per kilogram of body weight, with a typical patient requiring around 30 doses [6] Group 4: Pricing and Market Dynamics - The prices of immunoglobulin and albumin are expected to rise due to increased demand and limited supply, although the company will not raise prices during the pandemic [6][8] - The government is implementing policies to support the production of essential products during the pandemic, which may shorten the approval process for product releases [8] Group 5: Financial Performance Expectations - The company anticipates a year-on-year revenue growth of 5.00% to 25.00% for the first quarter, based on current conditions and previous year data [6][7] - The impact of the pandemic on the company's performance is expected to be minimal, with ongoing production in Guangdong being closely monitored by government officials [7]